Category: Oncology · Palliative Care · Clinical Research

Medical cannabis is attracting growing interest as a potential supportive treatment for people living with cancer. For patients experiencing pain, nausea, poor appetite, sleep disturbances, or other treatment-related symptoms, cannabis-based medicines may offer another avenue for symptom management. However, their effectiveness varies, and important questions remain about the safest dose, potential drug interactions, and which patients are most likely to benefit.

A September 2026 analysis of the CANPAN pilot trial examined the relationship between THC doses and symptom outcomes among patients with pancreatic cancer. Because the study involved a small number of participants, its findings should be interpreted cautiously. The research raises an important question: Could personalized cannabis dosing help improve quality of life for people with cancer while minimizing unwanted effects?

What Is Medical Cannabis, and How Does It Work?

Medical cannabis refers to cannabis-based products used under medical supervision to help manage particular symptoms or conditions. These products contain compounds called cannabinoids, which interact with biological systems involved in pain, appetite, nausea, mood, sleep, and other functions.

Two of the best-known cannabinoids are THC and CBD.

Tetrahydrocannabinol (THC) is the principal intoxicating component of cannabis. It can affect pain perception, appetite, nausea, mood, and sleep, but it may also cause dizziness, impaired concentration, anxiety, confusion, or other unwanted effects.

Cannabidiol (CBD) is another cannabinoid that does not typically produce the same intoxicating effects as THC. Although CBD is being studied for several potential therapeutic applications, evidence for its effectiveness against individual cancer-related symptoms remains variable.

The human endocannabinoid system includes receptors, naturally occurring compounds, and enzymes that help regulate several physiological processes. THC can interact with cannabinoid receptors, particularly CB1 receptors in the nervous system, influencing pain perception, appetite, and other functions. CBD interacts with the body through a more complex range of mechanisms.

Researchers are investigating whether these effects can be used to improve supportive cancer care. However, the biological plausibility of a treatment does not automatically establish that it works reliably in patients.

Medical cannabis should also be distinguished from cannabis products marketed without reliable medical oversight. Products can vary considerably in cannabinoid concentration, purity, route of administration, and consistency. These differences make it difficult to compare results between studies or determine which formulation might be appropriate for an individual patient.

What Did the September 2026 CANPAN Analysis Find?

The CANPAN research examined medical cannabis use among people with newly diagnosed, locally advanced or metastatic pancreatic cancer who were beginning standard chemotherapy.

The study was a small pilot randomized trial with a waitlist-control design. Thirty-two participants were assigned to receive access to a personalized cannabis intervention either during the first eight weeks or during weeks nine through sixteen.

The analysis published in The Oncologist on September 21, 2026, explored cannabis use over time and whether average daily THC exposure was associated with changes in symptoms.

32

Participants

The overall pilot study

Thirty-two patients entered the study, providing an initial opportunity to investigate feasibility, symptom monitoring, and personalized cannabis use.

23

Used cannabis

Participation in the intervention

Twenty-three participants, or 72% of the cohort, used cannabis during their assigned eight-week intervention period.

16

Analysed

Dose-response analysis

Only 16 participants had the required symptom assessments before cannabis use and eight weeks after starting it. This substantially limits confidence in the dose-response findings.

The researchers reported a statistically significant association between higher average daily THC exposure and improvements in anxiety and insomnia. The reported correlation coefficients were 0.52 for anxiety and 0.53 for insomnia. Participants averaging at least 10 milligrams of THC per day also experienced improvement in a greater mean number of symptoms than those using less than 10 milligrams daily.

These findings are interesting because they suggest that the relationship between dose and symptom relief may differ depending on the symptom being treated.

However, the study did not prove that increasing THC doses causes better outcomes. Participants were not randomly assigned to low-dose and high-dose groups. People who tolerated cannabis well or experienced early improvements might have chosen to use higher doses. That possibility, along with the small analysis sample, means the results are exploratory rather than a basis for a general dosing recommendation.

Can Personalized Doses Improve Quality of Life?

Personalized dosing means adjusting a treatment according to an individual’s symptoms, response, medical history, other medicines, and tolerance. In cancer care, the goal is not simply to reduce one symptom. It is to help people function more comfortably while minimizing treatment-related burdens.

Pancreatic cancer can cause several overlapping problems, including pain, nausea, reduced appetite, weight loss, anxiety, fatigue, and sleep disturbances. Chemotherapy and other treatments can add further complications.

A treatment that helps one patient sleep may do little for another patient’s appetite or pain. Similarly, a dose that produces noticeable relief for one person may cause excessive drowsiness or confusion in another.

This is why individualized symptom assessment is important. Rather than assuming that all patients need the same dose, researchers can investigate which formulations and exposure levels are associated with meaningful improvements in specific outcomes.

The CANPAN findings provide preliminary support for studying this approach. They do not establish a validated personalized dosing algorithm.

Why a one-size-fits-all approach may be inadequate

Patients differ in their sensitivity to THC, ability to tolerate side effects, underlying symptoms, nutritional status, liver function, and concurrent medications. The way a product is administered also affects how quickly its effects begin and how long they last.

For example, orally consumed products may take longer to produce effects than inhaled products, and their effects can be prolonged. This makes self-adjustment particularly risky when patients are already managing complex cancer treatment schedules.

Personalized care should therefore involve a qualified oncology clinician, careful review of medications, an appropriate product where legally available, and regular assessment of benefit and harm.

Which Cancer Symptoms Might Benefit?

Medical cannabis is being studied for several symptoms associated with cancer and its treatment. The strength of evidence differs by symptom, product, and clinical setting.

Cancer-related pain

Cannabinoids may influence pain processing, but clinical evidence for meaningful relief in cancer pain is mixed. They should not be assumed to replace established pain treatments, including appropriately prescribed analgesics.

Nausea and vomiting

Certain regulated cannabinoid medicines have established roles in specific cases of chemotherapy-induced nausea and vomiting, particularly when conventional antiemetic treatment has not been sufficient. This evidence does not mean every cannabis product is equally effective.

Insomnia and sleep disturbances

The CANPAN analysis found an association between higher daily THC exposure and improved insomnia symptoms. Larger controlled studies are needed to establish whether cannabis provides sustained sleep benefits and how it compares with other approaches.

Anxiety and emotional distress

The pilot analysis also found an association between higher THC exposure and improvements in anxiety. THC can itself provoke anxiety or paranoia in some people, so this result cannot be translated into a universal treatment recommendation.

Appetite and nutrition

THC can stimulate appetite in some settings, but increased appetite does not necessarily translate into weight gain, better nutritional status, or improved cancer outcomes. Persistent weight loss requires comprehensive nutritional and medical assessment.

The important distinction is between evidence that a cannabinoid can affect a biological process and evidence that a particular medical product improves a patient’s overall quality of life. Both are relevant, but they are not interchangeable.

For people receiving chemotherapy, symptom management should be coordinated with the oncology team. New or worsening nausea, severe pain, dehydration, inability to eat, or rapid weight loss may indicate a problem that requires prompt medical attention rather than simply a change in cannabis use.

Understanding THC Dose: Why More Is Not Always Better

One of the most interesting aspects of the CANPAN analysis is its examination of the relationship between THC exposure and symptom improvement.

In the dose-response analysis, participants with an average daily THC dose of at least 10 mg experienced improvement in a mean of four symptoms, compared with 2.1 symptoms among those averaging less than 10 mg daily. These figures describe the small study sample; they do not demonstrate that 10 mg is an optimal or safe dose for other patients.

Oxford Academic

+1

What the preliminary results showed

Mean number of symptoms that improved in each dose group

Average THC exposure below 10 mg/day

2.1

Average THC exposure of 10 mg/day or more

4.0

Source: CANPAN dose-response analysis. The bars illustrate the reported group averages, not the probability of treatment success.

Several explanations could account for this difference.

First, higher THC exposure might produce stronger effects on certain symptoms in some patients. Second, patients who tolerate THC well may be more likely to continue using it or increase their dose. Third, differences in symptoms, other treatments, and individual characteristics could influence the results.

The study cannot reliably separate these explanations.

Furthermore, a higher dose may increase unwanted effects, including dizziness, sedation, impaired attention, anxiety, and confusion. A patient who reports fewer symptoms but experiences substantial cognitive impairment may not have achieved a meaningful improvement in overall quality of life.

Future research should therefore examine both symptom relief and treatment burden. The best dose, if one can be established, would be the dose that produces a meaningful net benefit for a particular patient, rather than simply the highest tolerated dose.

How Could Clinicians Measure Quality-of-Life Improvements?

A personalized approach requires more than asking whether a patient feels better. Researchers need standardized ways to measure symptoms, everyday functioning, and adverse effects.

The CANPAN study used patient-reported symptom assessments, including the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), alongside a measure of global health and quality of life.

These assessments help researchers examine whether changes in treatment are accompanied by changes in patients’ experiences.

For example, a future clinical trial could evaluate the following outcomes:

• Pain: intensity, frequency, interference with everyday activities, and the need for rescue medication.
• Sleep: difficulty falling asleep, nighttime awakenings, sleep duration, and daytime alertness.
• Appetite and nutrition: food intake, body weight, hydration, and relevant nutritional measures.
• Emotional well-being: anxiety, distress, mood, and ability to participate in daily activities.
• Treatment safety: dizziness, confusion, falls, sedation, and possible interactions with other medicines.
• Overall quality of life: physical comfort, independence, social functioning, and the patient’s own assessment of treatment benefit.

Collecting these data at regular intervals could help identify patients who experience meaningful improvements and those who experience limited benefit or unacceptable side effects.

However, symptom tracking alone does not establish that cannabis caused an improvement. Researchers must also account for chemotherapy, other symptom-relieving medicines, disease progression, and changes in supportive care.

What Are the Risks of Medical Cannabis During Cancer Treatment?

Medical cannabis is not risk-free. Its effects depend on the product, dose, route of administration, patient characteristics, and other medications.

Cognitive and psychological effects

THC can impair attention, memory, judgment, coordination, and reaction time. Some patients experience anxiety, panic, paranoia, or confusion. Older adults and people who are already vulnerable to falls or cognitive difficulties may require particular caution.

Sedation can also interfere with daily functioning, increasing the risk of accidents or falls. Patients should avoid driving or operating machinery while impaired.

Drug interactions

Cannabinoids can affect drug-metabolizing enzymes and may interact with prescription medicines. This is especially important in oncology, where patients may receive several anticancer drugs, antiemetics, pain medicines, sedatives, anticoagulants, or other treatments.

The clinical significance of individual interactions varies. Patients should have their full medication list reviewed by an oncology clinician or pharmacist before starting a cannabis product.

Cannabis should not be assumed to enhance chemotherapy or make cancer treatment more effective. Claims that it treats or cures cancer are not established by the CANPAN findings.

Gastrointestinal and other adverse effects

Possible adverse effects include dry mouth, dizziness, changes in appetite, nausea, and gastrointestinal discomfort. Some patients can develop recurrent vomiting associated with prolonged, frequent cannabis use, a condition known as cannabinoid hyperemesis syndrome.

Inhaled products also carry respiratory concerns, and unregulated products can introduce additional risks through inaccurate labeling or contamination.

Risks associated with poor nutritional status

Pancreatic cancer can cause substantial weight loss, appetite changes, and digestive difficulties. Cannabis-related dizziness, sedation, or nausea could make eating and everyday activities more difficult for some patients.

Appetite stimulation alone does not address all the causes of cancer-associated weight loss. Nutritional support, management of digestive symptoms, and treatment of the underlying disease remain important.

Why Larger Clinical Trials Are Necessary

The CANPAN analysis is useful because it generates hypotheses that researchers can test in more rigorous studies. However, several limitations prevent its findings from supporting definitive clinical recommendations.

The sample was small. Although 32 participants were enrolled, only 16 contributed the required data for the dose-response analysis. Results from such a small group may not be reproducible in a larger population.

The study did not randomize participants to specific doses. Participants received individualized products and adjusted their use with guidance. This makes it difficult to determine whether higher THC exposure led to better outcomes or whether patients who responded well were more likely to use higher doses.

The intervention was open-label. Participants knew whether they were receiving the intervention, so expectations and other behavioral effects could have influenced self-reported symptoms.

Follow-up data were incomplete. Only half of the full cohort had patient-reported outcome data available at the end of the 16-week study period. Missing information can make estimates less reliable, especially if the reasons for missing data are related to treatment response or health status.

Patients were receiving other cancer treatments. Chemotherapy, disease progression, and changes in supportive care could influence pain, appetite, nausea, sleep, and psychological well-being.

The authors consequently presented the findings as exploratory and intended to inform future trial design, rather than as a basis for definitive dosing guidance.

What should the next generation of trials investigate?

Future trials could compare carefully defined cannabinoid formulations and dosing strategies while preserving appropriate medical supervision.

Researchers should consider larger, more diverse populations, randomized dose comparisons where ethically appropriate, standardized symptom measurements, and longer follow-up. They should also measure adverse effects and medication interactions systematically.

Another important question is whether certain symptoms respond more consistently than others. The CANPAN findings suggest that anxiety and insomnia deserve further investigation, but this hypothesis needs confirmation.

Researchers could also examine whether baseline symptom severity, age, concurrent medications, or other patient characteristics help predict benefit. Such information might eventually support more individualized treatment decisions.

Importantly, future trials should evaluate outcomes that matter to patients, including comfort, sleep, physical functioning, ability to eat, and overall quality of life, rather than relying exclusively on changes in individual symptom scores.

What Does This Research Mean for Patients in India?

For patients and families in India, the findings should be understood in the context of local laws and medical practice.

Cannabis and cannabis-derived preparations are subject to a complex regulatory framework in India. The legal status of a product depends on its composition, preparation, intended use, and applicable central and state rules. Different products cannot be assumed to have the same legal status simply because they are described as cannabis-based medicines.

Patients should consult a qualified oncologist and, where relevant, a pharmacist familiar with the applicable regulations before considering any cannabinoid product. Products obtained from informal sources may have uncertain THC concentrations, inconsistent quality, or contaminants.

It is particularly important not to substitute cannabis products for prescribed chemotherapy, immunotherapy, surgery, radiotherapy, pain treatment, or antiemetic medication. Anyone considering an additional treatment should discuss it with their cancer care team first.

Families can also help by keeping a record of symptoms, appetite, sleep, medication changes, and adverse effects. This information can support more informed discussions with clinicians, regardless of whether cannabis is part of the treatment plan.

The Future of Personalized Palliative Cancer Care

Personalized symptom management is an important goal in modern oncology. Patients with the same cancer diagnosis can have very different symptoms, treatment experiences, and priorities.

For one person, better sleep may be the most meaningful improvement. Another may prioritize pain relief, appetite, or the ability to remain alert enough to spend time with family. These differences underline the importance of evaluating treatment according to individual goals.

Medical cannabis is one area of ongoing research within supportive and palliative care. Its potential role should be assessed alongside established treatments, psychological support, nutrition, rehabilitation, and specialist palliative care.

The CANPAN analysis offers preliminary evidence that THC exposure may be associated with improvements in selected symptoms among patients with pancreatic cancer. However, it does not establish an optimal dose, demonstrate that higher doses cause better outcomes, or show that cannabis improves cancer survival.

The next step is not simply to prescribe more THC. It is to establish which patients might benefit, which symptoms are most responsive, what level of exposure is appropriate, and how potential benefits compare with adverse effects.

Conclusion

The September 2026 CANPAN analysis adds an important question to research on medical cannabis in oncology: could individualized cannabinoid treatment improve symptom control and quality of life for patients with difficult-to-treat cancers?

The preliminary findings are encouraging enough to justify further investigation. Higher daily THC exposure was associated with improvements in anxiety and insomnia, while the group averaging at least 10 mg per day experienced improvement in more symptoms on average. Yet these observations came from a small, non-randomized dose-response analysis and should not be interpreted as proof that a particular dose is effective or safe for everyone.

Larger, well-designed clinical trials are needed to establish the benefits, risks, and appropriate clinical role of medical cannabis in cancer care.

Ultimately, successful palliative treatment is not about maximizing the dose of any single medicine. It is about helping patients live as comfortably and meaningfully as possible while receiving safe, evidence-based care.